Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Reau

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
Journal of Clinical Gastroenterology|February 2, 2023
Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and OutcomesJessica Strzepka, Benjamin A Schwartz, Ethan M Ritz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 5, 2019
Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinomaAshwani K Singal, Sanjaya K Satapathy, Nancy Reau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United StatesMartin Hoenigl, Daniela Abramovitz, Ricardo E Flores Ortega, et al.
The American Journal of Gastroenterology|September 18, 2008
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirinNancy Reau, Stephanos J Hadziyannis, Diethelm Messinger, et al.
ACG Case Reports Journal|October 3, 2025
Guillain-Barré Syndrome Mimicking Autoimmune Hepatitis: A Rare EntityIbrahim Abdelmotelib, Dauris Rosario Lora, Omar Abdelhalim, et al.
Journal of Hepatology|February 9, 2012
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirinPatrick Marcellin, Nancy Reau, Peter Ferenci, et al.
Advances in Therapy|November 4, 2020
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis CMark Sulkowski, Wei-Han Cheng, Steven Marx, et al.
Infectious Diseases and Therapy|June 17, 2023
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV PatientsNancy Reau, Wei-Han Cheng, Qiujun Shao, et al.
Digestive Diseases and Sciences|March 7, 2015
Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?Shreya Sengupta, Kristen Wroblewski, Andrew Aronsohn, et al.
Journal of the Pediatric Infectious Diseases Society|January 19, 2026
Cost-effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United StatesJessica Frankeberger, Melissa Choz, Tatyana Kushner, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Journal of Clinical Gastroenterology|February 2, 2023
Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and OutcomesJessica Strzepka, Benjamin A Schwartz, Ethan M Ritz, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 5, 2019
Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinomaAshwani K Singal, Sanjaya K Satapathy, Nancy Reau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United StatesMartin Hoenigl, Daniela Abramovitz, Ricardo E Flores Ortega, et al.
The American Journal of Gastroenterology|September 18, 2008
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirinNancy Reau, Stephanos J Hadziyannis, Diethelm Messinger, et al.
ACG Case Reports Journal|October 3, 2025
Guillain-Barré Syndrome Mimicking Autoimmune Hepatitis: A Rare EntityIbrahim Abdelmotelib, Dauris Rosario Lora, Omar Abdelhalim, et al.
Journal of Hepatology|February 9, 2012
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirinPatrick Marcellin, Nancy Reau, Peter Ferenci, et al.
Advances in Therapy|November 4, 2020
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis CMark Sulkowski, Wei-Han Cheng, Steven Marx, et al.
Infectious Diseases and Therapy|June 17, 2023
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV PatientsNancy Reau, Wei-Han Cheng, Qiujun Shao, et al.
Digestive Diseases and Sciences|March 7, 2015
Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?Shreya Sengupta, Kristen Wroblewski, Andrew Aronsohn, et al.
Journal of the Pediatric Infectious Diseases Society|January 19, 2026
Cost-effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United StatesJessica Frankeberger, Melissa Choz, Tatyana Kushner, et al.
Pageof 10